Eli Lilly and Company has emerged as in the development and tirzepatide, a groundbreaking drug for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrates significant potential to improve glycemic control and reduce heart disease. The sophisticated synthesis of tirzepati